title: [Comment to the status article about denosumab].
authors.forename: Klaus
authors.initials: K
authors.lastname: Brasso
authors.forename: Peter
authors.initials: P
authors.lastname: Iversen
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000069448:Denosumab; D006801:Humans; D008297:Male; D057466:Nonsteroidal Anti-Androgens / Q000009:adverse effects / Q000627:therapeutic use; D058866:Osteoporotic Fractures / Q000188:drug therapy / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000188:drug therapy; D053245:RANK Ligand / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057466:Nonsteroidal Anti-Androgens; D053245:RANK Ligand; D000069448:Denosumab